Clinical Trials

350 enrolled

Triple Negative Breast Neoplasms

NCT04722978 2025-12-17

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

Phase 3 Recruiting

228 enrolled

Triple Negative Breast Neoplasms

NCT05347134 2025-12-09

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

254 enrolled

Triple Negative Breast Neoplasms

NCT06382142 2025-11-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

418 enrolled

Triple Negative Breast Neoplasms

NCT03371017 2025-11-12

IMpassion132

595 enrolled 37 charts

Triple Negative Breast Neoplasms

NCT05382299 2025-09-05

ASCENT-03

623 enrolled

Triple Negative Breast Neoplasms

NCT02819518 2024-11-27

KEYNOTE-355

882 enrolled 41 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT04799249 2024-08-01

PRESERVE 2

194 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03002103 2023-04-26

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

Phase 3 Suspended

420 enrolled

Triple Negative Breast Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

622 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT01287624 2015-03-23

TNBC

240 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00938652 2013-09-19

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

519 enrolled